R1 RCM is mentioned as a competitor with lower gross margins due to reliance on manual labor, contrasting with Waystar's superior performance.
Source Post
The creator highlights Waystar (WAY) as a stock with significant growth potential in the healthcare AI sect...
Jul 5, 2026
The creator highlights Waystar (WAY) as a stock with significant growth potential in the healthcare AI sector. They emphasize Waystar's advanced AI capabilities, strong revenue growth, and superior gross margins compared to competitors, suggesting the market is mispricing the stock due to a misunderstanding of its seasonal enterprise onboarding.
Linked Mentions
Tickers discussed in this post
Waystar is presented as a strong buy due to its AI-driven growth, high gross margins, and market mispricing.
Linked Signals
Tracked calls opened from this post
WAYbuy opened Jul 5, 2026
-5.84%